[1] Duan XH, Zhou HH. Induction mechanism and research progress of CYP2C9. Chin Pharmacol Bull, 2004,20(9):961-965.
[2] Taube J, Halsall D, Baqlin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood, 2000, 96(5):1816-1819.
[3] Margaglione M, Colaizzo D, D’Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost, 2000,84(5):775-778.
[4] Miners JO, Coulter S, Birkett DJ, et al. Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes. Pharmacogenetics, 2000,10(3):267-270.
[5] Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol, 1996,49(2):311-318.
[6] Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA, 1998,95(22):13176-13181.
[7] Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet, 2001,27(4):383-391.
[8] Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther, 2001,70(2):189-199.
[9] Dai S, Mao C, Jiang L, et al. P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case–control studies. Human Genetics, 2009,125(5-6):633-638.
[10] Stehle S, Kirchheiner J, Lazar A, et al. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet, 2008,47(9):565-594.
[11] Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med, 2008,358(10):999-1008.
[12] Zhu Y, Shennan M, Reynolds K K, et al. Estimation of warfarin maintenance dose based on VKORC1(-1639 G>A)and CYP2C9 genotypes. Clin Chem, 2007,53(7):1721-1722.
[13] Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med,2005,352(22):2285-2293.
[14] Ottmann OG, Wassmann B, Pfeifer H, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph+ALL). Cancer, 2007,109(10):2068-2076.
[15] Merx K, Muller MC, Kreil S, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia, 2002,16(9):1579-1583.
[16] Trudel S, Stewart AK, Rom E, et al. The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood, 2006,107(10):4039-4046.
